Market icon

Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?

Market icon

Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?

If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.

The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.

Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
Volume
$29,057
End Date
Apr 1, 2022
Market Opened
Jan 24, 2022, 7:00 PM ET
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”. The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America. Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.

Outcome proposed: No

No dispute

Final outcome: No

If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.

The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.

Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
Volume
$29,057
End Date
Apr 1, 2022
Market Opened
Jan 24, 2022, 7:00 PM ET
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”. The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America. Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.

Outcome proposed: No

No dispute

Final outcome: No

Beware of external links.

Frequently Asked Questions

"Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?" is a prediction market on Polymarket where traders buy and sell "Yes" or "No" shares based on whether they believe this event will happen. The current crowd-sourced probability is 0% for "Yes." For example, if "Yes" is priced at 0¢, the market collectively assigns a 0% chance that this event will occur. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

As of today, "Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?" has generated $29.1K in total trading volume since the market launched on Jan 25, 2022. This level of trading activity reflects strong engagement from the Polymarket community and helps ensure that the current odds are informed by a deep pool of market participants. You can track live price movements and trade on any outcome directly on this page.

To trade on "Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?," simply choose whether you believe the answer is "Yes" or "No." Each side has a current price that reflects the market's implied probability. Enter your amount and click "Trade." If you buy "Yes" shares and the outcome resolves as "Yes," each share pays out $1. If it resolves as "No," your "Yes" shares pay $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current probability for "Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?" is 0% for "Yes." This means the Polymarket crowd currently believes there is a 0% chance that this event will occur. These odds update in real-time based on actual trades, providing a continuously updated signal of what the market expects to happen.

The resolution rules for "Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.